Next-generation multivalent and bispecific biologics
This article was originally published in Start Up
Next-generation bispecific “antibody-like” protein drug technologies boast the as-yet-unproven ability to deliver synergistically dual-acting therapeutics with the properties of two monoclonal antibodies in a single molecule, but the key to these emerging technologies’ success depends on their protein-binding moieties. Covagen AG contends that its Fynomers technology solves many of the problems that hold back current bispecific antibody therapies.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.